Preliminary analysis show increased antibody response against Beta, Delta, Alpha, Gamma, and Omicron variants after the third booster dose with Vaxzevria. AstraZeneca said on Thursday, commenting a study on the matter.
The results were obtained following vaccination either with Vaxzevria or with an mRNA vaccine, said the company. Therefore, the new findings support Vaxzevria as a third booster dose regardless of the primary immunization schedules tested.
"Vaxzevria has protected hundreds of millions of people from COVID-19 around the world and these data show, that it has an important role to play as a third dose booster, including when used after other vaccines. Given the ongoing urgency of the pandemic and Vaxzevria's increased immune response to the Omicron variant, we will continue to progress regulatory submissions around the world for its use as a third dose booster," stated Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.
